Manufacturing partner Asimov has recently announced collaborations and platform launches aimed at scalable and affordable biologics and gene therapy manufacturing, presenting a clear opportunity to position partners for joint development, contract manufacturing, and technology licensing with their Chrysalis transposase, CHO Edge Rapid Pools, and AAV Edge systems.

AI driven design The company blends artificial intelligence with synthetic biology for design and optimization of therapeutics, suggesting sales potential for computational design services, data analytics partnerships, and integration of AI tools with client workflows to accelerate product development.

Therapeutic focus Active emphasis on biologics and gene therapies, including RNA therapies, indicates upsell opportunities in mRNA or RNA-based modalities, alongside process development and analytical systems compatible with high-value therapeutics.

Expansion momentum A steady stream of product launches and partnerships in 2025–2026 shows rapid productization and ecosystem growth, signaling readiness for collaboration on custom cell line development, platform integration, and scalable manufacturing solutions.

Global collaborations Recent collaborations with Mabylon AG and Score Pharma indicate openness to international partnerships and co-development, offering avenues to pursue joint ventures, distribution deals, or regional manufacturing and supply agreements.